Bausch Health Canada announces CABTREO availability via public drug plans

Bausch Health (BHC), Canada announced that CABTREO gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris, is now available to beneficiaries of the public drug plans of Quebec and Saskatchewan. This new public drug plan availability of CABTREO is in addition to that announced last month for those using the Ontario and Nova Scotia public drug plans as well as through the federal government’s Non-Insured Health Benefits drug plan for Indigenous populations as well as those of the Correctional Service of Canada and Veterans Affairs Canada.